Some in Drug Industry Fear Inflation Reduction Act Could Hinder Drug Innovation

August 11, 2022 by Alexa Hornbeck
Some in Drug Industry Fear Inflation Reduction Act Could Hinder Drug Innovation

WASHINGTON — The Senate passed the roughly $740 billion tax, climate and health care package known as the Inflation Reduction Act on Aug. 7, by a vote of 51-50. The massive package includes provisions to reduce drug costs for patients and providers by letting Medicare negotiate prices for older drugs that don’t have competition, but some in the industry have concerns over whether this portion of the bill will hinder innovation. 

“Our reading of the bill is that this would have an effect on the ability to bring generic or biosimilar products into market,” said an industry source during a phone call with The Well News.

If the bill passes, it would give Medicare the ability to negotiate with manufacturers for 10 drugs starting in 2026, and 20 drugs within a decade. The bill imposes a penalty of 95% of sales from the year before for any drug manufacturers who do not engage in the negotiations. 

“You can have a drug, nine years down the road, subject to government price setting, and could have spent five years doing [research and development],” the industry source said. 

“The bill doesn’t recognize the value of additional research in R&D,” the source said. 

The bill could impact innovation and lead to fewer cures and treatments, but the question remains of how big will the impact be, the industry source said.

They went on to say the bill doesn’t address the underlying problems patients are experiencing due to insurance design issues.

“It’s a drug pricing bill, but not much is done to fix the drug pricing problem,” they said.

The industry source said that more than 50 cents of every dollar spent on medicines goes to other actors who aren’t actually developing the medicine, and drug spending currently accounts for 14% of the overall health care spending in the country. 

Drugs average 14 years on the market before facing generic competition, according to a letter penned by over 1,200 patients, patient advocates, researchers and small company executives and employees. 

The letter was sent to Senate Majority Leader Chuck Schumer, D-N.Y., chairman of the Senate Finance Committee, Ron Wyden, D-Ore., and members of the U.S. Senate on July 25, indicating they feel that the Senate drug bill fails to deliver adequate relief to the nation’s seniors and families, and is, “bad for biopharma innovation.” 

The Senate bill also proposes to cap the out-of-pocket costs for Medicare beneficiaries to $2,000 by 2025, but the letter writers allege that fewer than 900,000 of the more than 32 million non-Medicaid eligible Medicare beneficiaries had out-of-pocket costs above the $2,000 cap in 2019. 

The bill also increases Part D cost sharing for all beneficiaries from 23% to 25%, but repeals a requirement that health insurers and pharmacy benefit managers pass prescription drug discounts on to patients. 

“Seniors will have no protection from Medicare Advantage plans and PBMs that can continue to pocket savings, even when the government does the negotiation for them,” it says in the letter. 

Since 2016, fewer than half of the drugs which received first approval by the FDA to permit a manufacturer to market certain generic drugs, known as first generics, are commercially available to patients, according to Allen Goldberg, who serves as senior vice president of communications for the Association for Accessible Medicines, a trade association representing the manufacturers and distributors of generic prescription drugs, in an email to The Well News.

Of those the first generics that are commercially available, Goldberg said data shows that only about half were included on formularies of Medicare Part D plans. 

“Once they are added to formularies, first generics are routinely placed on expensive brand drug tiers with higher patient copays, rather than on generic tiers with lower cost-sharing. As a result, seniors do not benefit from lower prices and lower out-of-pocket costs, and taxpayers continue to pay for high-priced brand drugs,” Goldberg said.

“The price setting … will only reduce competition, harm future savings from generic and biosimilar medicines, and increase costs for employers and patients with private insurance,” Goldberg continued.

Despite concerns raised by some in the industry, a report from the Congressional Budget Office finds that Medicare negotiations would not have a big impact, with estimates that 15 out of 1,300 drugs, or 1%, would not make it to market as a result in the next 30 years. 

“Most of the work we will do will be unaffected by the timelines, as it doesn’t go into effect until 2026, and the impact of the bill is not a negative for us,” said David Sanders, who serves as vice president of government affairs and policy at Coherus Biosciences, a biosimilar company working to expand patient access to life changing medicines in regulated markets, during a phone call with The Well News. 

“[However,] we need more encouragement for competition in Medicare Part D,” said Sanders.

Sanders said there are 31 drugs approved as biosimilars, which are administered to a vast majority hospital and physicians under Medicare Part B.

“If it’s one thing we missed in this bill it’s to encourage Medicare to award American products … [to] create more incentives,” said Sanders. 

The House is set to vote on the legislation Friday.

Alexa can be reached at [email protected] 

A+
a-

Corrections

This story has been corrected to reflect that David Sanders, of Cohrus Biosciences, was referring to Medicare Part B when talking about the 31 drugs approved as biosimilars.

Updates

Corrected quote from spokesperson to read 50 cents

  • drug innovation
  • Inflation Reduction Act
  • In The News

    Health

    Voting

    Health

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    March 26, 2024
    by Dan McCue
    Consumers Warned to Avoid Certain Topical Pain Relief Products 

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed... Read More

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed for topical use before, during or after certain cosmetic procedures. The warning came after the agency issued warning letters to six companies for marketing these products... Read More

    News From The Well
    scroll top